Skip Navigation

Annals of Oncology 2007 18(3):407-408; doi:10.1093/annonc/mdl503
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Zandwijk, N
Right arrow Articles by van de Vijver, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Zandwijk, N
Right arrow Articles by van de Vijver, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorial

clairvoyance or reliable prediction of the future?

N van Zandwijk1,* and MJ van de Vijver2

1 Department of Thoracic Oncology, Netherlands Cancer Institute
2 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

* E-mail: n.v.zandwijk@nki.nl

The first 10% of the full text of this article appears below.

The first reports showing that the epidermal growth factor receptor (EGFR) is expressed in non-small-cell lung cancer (NSCLC) appeared two decades ago [1]. This has led to many attempts to interact with EGFR signaling, but it was not until some 4 years ago that the first positive experiences with gefitinib and erlotinib in patients with recurrent NSCLC were reported [2–4].

Treatment with both of these small molecules, that inhibit the tyrosine kinase domain of the EGFR (EGFR TKIs), has been marked by favorable clinical responses in distinct groups of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?